Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group
- PMID: 9890172
- DOI: 10.1093/jnci/91.1.66
Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group
Abstract
Background: Vinorelbine, a semisynthetic vinca alkaloid, represents a well-tolerated treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC). We explored the quality of life (QoL) of such patients in a multicenter randomized trial that compared vinorelbine treatment with supportive care alone.
Methods: Eligible patients were 70 years of age or older, had stage IV or IIIB NSCLC that was ineligible for radiotherapy, and had a performance status of 0-2 (a status of fully active to a status of capable of all self-care but unable to work). Vinorelbine was given intravenously on days 1 and 8 of a 21-day treatment cycle, for a total of six cycles. QoL was evaluated with European Organization for Research and Treatment of Cancer questionnaires QLQ-C30 and QLQ-LC13, and the QoL data were analyzed by fitting a linear mixed model for each QoL scale. Survival curves were plotted and were compared with the Mantel-Haenszel test. Relative hazards of death and 95% confidence intervals (CIs) were estimated by the Cox model.
Results: Investigators, blinded to the results, stopped the trial early because of a low enrollment rate. (From April 1996 to November 1997, 191 of the 350 targeted patients were randomly assigned.) Data from 161 patients have been analyzed. Vinorelbine-treated patients scored better than control patients on QoL functioning scales, and they reported fewer lung cancer-related symptoms but reported worse toxicity-related symptoms. There was a statistically significant (two-sided P = .03) survival advantage for patients receiving vinorelbine; median survival increased from 21 to 28 weeks in the vinorelbine-treated group. The relative hazard of death for vinorelbine-treated patients was 0.65 (95% CI = 0.45-0.93).
Conclusion: Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall QoL.
Comment in
-
Re: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.J Natl Cancer Inst. 2002 Jul 3;94(13):1029-30; author reply 1030-1. doi: 10.1093/jnci/94.13.1029. J Natl Cancer Inst. 2002. PMID: 12096088 No abstract available.
Similar articles
-
Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.Drugs Aging. 2002;19(9):695-721. doi: 10.2165/00002512-200219090-00006. Drugs Aging. 2002. PMID: 12381238 Review.
-
The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study.Oncologist. 2001;6 Suppl 1:4-7. doi: 10.1634/theoncologist.6-suppl_1-4. Oncologist. 2001. PMID: 11181997 Clinical Trial.
-
Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study.Eur J Cancer. 1997 Mar;33(3):392-7. doi: 10.1016/s0959-8049(97)89011-9. Eur J Cancer. 1997. PMID: 9155522 Clinical Trial.
-
Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.J Natl Cancer Inst. 2005 Apr 6;97(7):499-506. doi: 10.1093/jnci/dji096. J Natl Cancer Inst. 2005. PMID: 15812075 Clinical Trial.
-
Update: vinorelbine (navelbine) in non-small cell lung cancer.Semin Oncol. 1996 Apr;23(2 Suppl 5):2-7. Semin Oncol. 1996. PMID: 8610232 Review.
Cited by
-
Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis.Sci Rep. 2020 Oct 16;10(1):17536. doi: 10.1038/s41598-020-73466-6. Sci Rep. 2020. PMID: 33067482 Free PMC article.
-
Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323.Transl Lung Cancer Res. 2020 Jun;9(3):459-470. doi: 10.21037/tlcr.2020.03.29. Transl Lung Cancer Res. 2020. PMID: 32676310 Free PMC article.
-
Gemcitabine and carboplatin combination chemotherapy for elderly patients with advanced Non-Small Cell Lung Cancer: a feasibility study.Cancer Res Treat. 2008 Sep;40(3):116-20. doi: 10.4143/crt.2008.40.3.116. Epub 2008 Sep 30. Cancer Res Treat. 2008. PMID: 19688117 Free PMC article.
-
Oral anticancer drugs in the elderly: an overview.Drugs Aging. 2007;24(5):395-410. doi: 10.2165/00002512-200724050-00004. Drugs Aging. 2007. PMID: 17503896 Review.
-
Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L).JTO Clin Res Rep. 2023 Aug 23;4(10):100569. doi: 10.1016/j.jtocrr.2023.100569. eCollection 2023 Oct. JTO Clin Res Rep. 2023. PMID: 37822699 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous